Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome

Figures & data

Figure 1 The change in number of stools per week throughout the duration of the study.

Abbreviation: BM, bowel movement.

Table 1 Changes in gastrointestinal symptom scores in both groups between the screening week and end of treatment

	Groups	Screening week, mean±SD	End of treatment (week 3), mean±SD	P-value
Number of stools per week	Placebo	19.7±8.3	15.5±13.6	0.12
	SBI	18±5.3	13.6±5.4	0.07
Abdominal pain (Likert scale: 0 no pain; 4, severe pain)	Placebo	2.1±0.7	1.6±0.7	0.08
	SBI	2.4±0.6	1.7±0.9	0.02
Stool form (Bristol stool scale: 1–7)	Placebo	5.1±0.6	4.2±2	0.28
	SBI	5.3±0.8	4.2±1.2	0.05

Abbreviation: SBI: serum-derived bovine immunoglobulin.

Table 2 Changes in FDI and PedsQOL scores in placebo and SBI groups between the screening week and end of treatment

	SBI			Placebo
	Screening, mean±SD	Week 3, mean±SD	P-value	Screening, mean±SD	Week 3, mean±SD	P-value
FDI	20.4±4	8.3±2	0.01	16±3	12.3±3	0.23
PedsQOL	53.3±5	74±5	0.01	52±4	62.3±6	0.14
Pain score	32.5±6	67.2±7	0.008	32.6±5	45.1±6	0.15
Postprandial discomfort	54.4±7	78.8±7	0.01	51.7±7	54±3	0.78
Diarrhea	48.2±9	75.4±7	0.009	39.6±8	62.5±8	0.06
Worry about pain	19.6±10	48.2±9	0.03	25±10	41.7±7	0.27
Communication	51.4±13	75±10	0.03	47.5±12	57.5±1	0.26

Abbreviations: FDI, Pediatric Functional Disability Index; PedsQOL, Pediatric Quality of Life Inventory^™ for Gastrointestinal Symptoms; SBI, serum-derived bovine immunoglobulin.